Corcept Therapeutics Faces Legal Probe After FDA Rejection Triggers Stock Crash

Kaplan Fox & Kilsheimer LLP has launched an investigation into potential securities law violations by Corcept Therapeutics (NASDAQ: CORT). The legal probe follows a massive 50% plunge in the company's share price after the FDA issued a Complete Response Letter rejecting its drug, relacorilant. Investor concerns deepened after a subsequent FDA correction revealed the agency had previously warned the company about clinical program inadequacies. This previously undisclosed regulatory friction led to an additional 12% drop in the stock price as transparency issues came to light. The investigation aims to determine if Corcept misled shareholders regarding the viability of its clinical trials and regulatory standing. With significant losses and potential class-action litigation, the outlook for CORT remains heavily bearish in the near term.